OncView™ Podcast: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management in Metastatic RCC
In an OncView™ program, David H. Aggen, MD, PhD, Robert S. Alter, MD, Arnab Basu, MD, MPH, FACP, Mehmet Asim Bilen, MD, and Chung-Han Lee, MD, MPH, offer their expert insights for the treatment of RCC.
As part of its OncView™ video series, CancerNetwork® spoke with David H. Aggen, MD, PhD, of Memorial Sloan Kettering Cancer Center, Robert S. Alter, MD, of the John Theurer Cancer Center, Arnab Basu, MD, MPH, FACP, of the O’Neal Comprehensive Cancer, Mehmet Asim Bilen, MD, of Winship Cancer Institute, and Chung-Han Lee, MD, MPH, of Memorial Sloan Kettering Cancer Center, share their thoughts on recent advances in treatment options for metastatic renal cell carcinoma (RCC) and comment on emerging data in the field.
In the video series, some of the content discussed included:
- Trends in RCC Incidence
- Risk Models and Prognostic Factors
- Biomarker Testing in RCC: Current Approaches
- Comparison of Older First-Line, Single-Agent Therapies
- Newer First-Line Combination Therapy Options
To watch more videos in the CancerNetwork® OncView™ series, visit cancernetwork.com/oncview.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
EP: 1.Trends in RCC Incidence
EP: 2.RCC Histologies
EP: 3.Risk Models and Prognostic Factors
EP: 4.Metastatic RCC: Prognosis and Recent Advances in Care
EP: 5.Biomarker Testing in RCC: Current Approaches
EP: 6.Biomarker Testing: Methodologies, Sample Types, and Emerging Data
EP: 7.Prognostic Value of Biomarkers in RCC
EP: 8.The Role of Genetic Mutations in Prognosis and Decision-Making
EP: 9.Comparison of Older First-Line, Single-Agent Therapies
EP: 10.Newer First-Line Combination Therapy Options
EP: 11.Evolution of Combination Therapy As The Standard of Care
EP: 12.Patients Suitable for First-Line, Single-Agent Therapy and NCCN-Recommended Regimens
EP: 13.Safety and Efficacy Data: The CheckMate 214 Trial
EP: 14.Safety and Efficacy Data: The JAVELIN Renal 101 Trial
EP: 15.Safety and Efficacy Data: The KEYNOTE-426 Trial
EP: 16.Safety and Efficacy Data: The CheckMate 9ER Trial
EP: 17.Safety and Efficacy Data: The CLEAR Trial
EP: 18.Common Adverse Events with Single-Agent or Combination Therapy
EP: 19.Balancing Treatment Efficacy with Toxicity in Metastatic RCC
EP: 20.Strategies for Prevention and Management of Adverse Events
EP: 21.Patient-Specific Factors Impacting Treatment Choices in RCC
EP: 22.Considerations for Patient-Focused, Shared Decision-Making in RCC
EP: 23.Clinical Pearls on Tailoring Dosing Strategies in Metastatic Kidney Cancer
EP: 24.The Importance of Team-Based Management and Patient Communication
EP: 25.OncView™ Podcast: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management in Metastatic RCC
EP: 26.Reflections on Novel Targets and Emerging Regimens for RCC
EP: 27.Clinical Pearls on Recent Advances and the Future of Treatment in RCC
EP: 28.Recap: Safety and Efficacy of Available Treatment Options and Considerations for Management of RCC
Belzutifan Improves PFS Across Subgroups for Advanced ccRCC
July 12th 2024“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.
